Mibefradil hydrochloride. Antihypertensive, calcium antagonist

Drugs of the Future

Volumn 22, Issue 10, 1997, Pages 1091-1102

  Casas, A ^a   Graul, A ^b   Castaner J ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; CALCIUM ANTAGONIST; DIGOXIN; DILTIAZEM; ENALAPRIL; HYDROCHLOROTHIAZIDE; LISINOPRIL; MIBEFRADIL; NIFEDIPINE; UNCLASSIFIED DRUG; VERAPAMIL;

ANTIHYPERTENSIVE ACTIVITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG METABOLISM; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; REVIEW; TOXICITY TESTING;

EID: 0031466542     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1997.022.10.426725     Document Type: Review

References (118)

1. Branca, Q., Jaunin, R., Märki, H.P., Marti, F., Ramuz, H. (F. Hoffmann-La Roche AG). Tetrahydronaphthalene derivs. and medicines containing them. EP 268148, JP 88139171, US 4808605.
2. Clozel, J.-P., Osterrieder, W., Kleinbloesem, C.H., Welker, H.A., Schläppi, B., Tudor, R., Hefti, F., Schmitt, R., Eggers, H. Ro 40-5967: A new nondihydropyridine calcium antagonist. Cardiovasc Drug Rev 1991, 9: 4-17.
3. 2+ channel blocker with potent vasodilator but weak inotropic action. J Cardiovasc Pharmacol 1989, 13: 754-9.
4. Bühler, F.R., Fleckenstein-Grün, G., Clozel, J.-P., Reid, J.L., Rousseau, M.F., Triggle, D.J., Tsien, R.W. Mibefradil, a new class of calcium antagonists: From molecular biology to clinical benefit. J Cardiovasc Pharmacol 1996, 27(Suppl. A): S1-3.
5. Clozel, J.-P. Pharmacology of the new calcium antagonist mibefradil. J Cardiovasc Pharmacol 1996, 27(Suppl. A): S17-21.
6. Kobrin, I., Charlon, V., Lindberg, E., Neumann, N., Pordy, R. Mibefradil: A new T-channel selective calcium antagonist. Med Actual/Drugs Today 1997, 33: 523-42.
7. Orito, K., Satoh, K., Taira, N. Cardiovascular profile of Ro 40-5967, a new nondihydropyridine calcium antagonist, delineated in isolated, blood-perfused dog hearts. J Cardiovasc Pharmacol 1993, 22: 293-9.
8. 3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts. Cardiovasc Drugs Ther 1990, 4: 731-6.
9. Ezzaher, A., Bouanani, N., Su, J., Hittinger, L., Crozatier, B. Increased negative inotropic effect of calcium channel blockers in hypertrophied and failing rabbit heart. J Pharmacol Exp Ther 1991, 257: 466-71.
10. 2+ inward currents by Ro 40-5967 and verapamil: Relation to negative inotropy. Eur J Pharmacol 1991, 196: 205-7.
11. 2+ channel antagonist Ro 40-5967 in vascular muscle cells cultured from dog coronary and saphenous arteries. Naunyn-Schmied Arch Pharmacol 1993, 348: 191-6.
12. 2+ channels by Ro 40-5967. J Pharmacol Exp Ther 1994, 269: 178-83.
13. 2+ channels by Ro 40-5967. Circ Res 1994, 75: 144-8.
14. 2+-agonistic effect of a novel cardiovascular drug mibefradil (Ro 40-5967). Pharmacol Res 1995, 31(Suppl.): 240.
15. 2+ in dog coronary arterial vascular muscle cells by Ro 40-5967. J Cardiovasc Pharmacol 1994, 24: 1-7.
16. Véniant, M., Clozel, J.-P., Hess, P., Wolfgang, R. Hemodynamic profile of Ro 40-5967 in conscious rats: Comparison with diltiazem, verapamil, and amlodipine. J Cardiovasc Pharmacol 1991, 18(Suppl. 10): S55-8.
17. Hefti, F., Clozel, J.-P., Osterrieder, W. Antihypertensive properties of the novel calcium antagonist (1S,2S)-2-[2-[[3-(2-benzimidazolyl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4- tetrahydro-1-isopropyl-2-naphthyl methoxyacetate dihydrochloride in rat models of hypertension. Comparison with verapamil. Arzneim-Forsch-Drug Res 1990, 40: 417-21.
18. 2+ channel inhibitor Ro 40-5967 potentiates endothelium-dependent relaxations in the aorta of the hypertensive salt sensitive Dahl rat. Pharmacologist 1993, 35(3): Abst 173.
19. Vacher, E., Richer, C., Fornes, P., Clozel, J.-P., Giudicelli, J.-F. Mibefradil, a selective calcium T-channel blocker, in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 1996, 27: 686-94.
20. Clozel, J.-P., Banken, L., Osterrieder, W. Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: Comparison with verapamil. J Cardiovasc Pharmacol 1989, 14: 713-21.
21. Guth, B. Reduction of exercise-induced regional contractile dysfunction in dogs with a novel calcium antagonist (Ro 40-5967). Cardiovasc Drugs Ther 1991, 5(Suppl. 3): Abst P493.
22. Guth, B.D. Reduction of exercise-induced regional contractile dysfunction in dogs using a novel calcium channel blocker (Ro 40-5967). Cardiovasc Drugs Ther 1992, 6: 167-71.
23. Mulder, P., Richard, V., Henry, J.P., Clozel, J.P., Lallemand, F., Macé, B., Thuillez, C. The calcium antagonist mibefradil increases survival in a rat model of chronic heart failure. Amer J Hypertension 1996, 9(4, Part 2): 147A.
24. Skerjanec, A., Tam, Y.K. HPLC analysis of Ro 40-5967 in human and dog plasma. Pharm Res 1993, 10(10, Suppl.): Abst APQ 1176.
25. Skerjanec, A., Tam, Y.K. Pharmacokinetics of Ro 40-5967 in chronically instrumented dogs. Pharm Res 1994, 11(10, Suppl.): Abst PPDM 8285.
26. Skerjanec, A., Tawfik, S., Tam, Y.K. Mechanisms of nonlinear pharmacokinetics of mibefradil in dogs: Presystemic first-pass consideration. Pharm Res 1995, 12(9, Suppl.): Abst PPDM 8061.
27. Skerjanec, A., Tawfik, S., Tam, Y.K. Mechanisms of nonlinear pharmacokinetics of mibefradil in chronically instrumented dogs. J Pharmacol Exp Ther 1996, 278: 817-25.
28. Welker, H.A., Eggers, H., Kleinbloesem, C., Erb, K., Breithaupt, K., Butzer, R., Belz, G.G. Ro 40-5967: Pharmacokinetics of a new calcium antagonist. Eur J Clin Pharmacol 1989, 36(Suppl.): Abst PP 14.19.
29. Wiltshire, H.R., Harris, S.R., Prior, K.J., Kozlowski, U.M., Worth, E. Metabolism of calcium antagonist Ro 40-5967: A case history of the use of diode-array u.v. spectroscopy and thermospray-mass spectrometry in the elucidation of a complex metabolic pathway. Xenobiotica 1992, 22: 837-57.
30. Wiltshire, H.R., Sutton, B.M., Heeps, G., Betty, A.M., Angus, D.W., Madigan, M.J., Sharp, S.R. Metabolism of the calcium antagonist, mibefradil (Posicor™, Ro 40-5967). Part II. Metabolism in hepatic microsomes from rat, marmoset, cynomolgus monkey, rabbit and man. Xenobiotica 1997, 27: 539-56.
31. Wiltshire, H.R., Sutton, B.M., Heeps, G., Betty, A.M., Angus, D.W., Harris, S.R., Worth, E., Welker, H.A. Metabolism of the calcium antagonist, mibefradil (Posicor™, Ro 40-5967). Part III. Comparative pharmacokinetics of mibefradil and its major metabolites in rat, marmoset, cynomolgus monkey and man. Xenobiotica 1997, 27: 557-71.
32. Schmitt, R., Kleinbloesem, C.H. Ro 40-5967, a calcium antagonist of a new generation? Eur J Clin Pharmacol 1989, 36(Suppl.): Abst PP 16.26.
33. Rosenquist, M., Brembilla-Perrot, B., Meinertz, T., Neugebauer, A., Crijns, H.J.M.G., Smeets, J.L.R.M., van der Vring, J.A.F.M., Fromer, M., Kobrin, I. The acute effects of intravenously administered mibefradil, a new calcium antagonist, on the electrophysiologic characteristics of the human heart. Eur J Clin Pharmacol 1997, 52: 7-12.
34. Schmitt, R., Kleinbloesem, C.H., Belz, G.G. et al. Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension. Clin Pharmacol Ther 1992, 52: 314-23.
35. Bernink, P.J.L.M., Prager, G., Schelling, A., Kobrin, I. Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967). Hypertension 1996, 27: 426-32.
36. Oparil, S., Kobrin, I., Abernethy, D., Levine, B., Reif, M., Sheperd, A. Dose-response characteristics of mibefradil, a novel calcium antagonist in the treatment of essential hypertension. Amer J Hypertension 1997, 10: 735-42.
37. Bursztyn, M., Kadr, H., Tilvis, R., Martina, B., Oigman, W., Talberg, J., Kobrin, I. Mibefradil, a novel calcium antagonist, in elderly patients with hypertension: Favorable hemodynamics and pharmacokinetics. Amer Heart J 1997, 134: 238-47.
38. Carney, S., Wing, L., Ribeiro, A., Kallwellis, R., Zimlichman, R., Viskoper, R., Mion, D., Kobrin, I. The addition of mibefradil to chronic hydrochlorothiazide treatment in hypertensive patients is associated with a significant antihypertensive effect. J Hum Hypertension 1997, 11: 459-66.
39. Lacourcière, Y., Poirier, L., Lefebvre, J., Archambault, F., Dalla Ave, S., Ward, C., Lindberg, E. The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension. Amer J Hypertension 1997, 10: 189-96.
40. Viskoper, R., Bernink, P., Schelling, A., Ribeiro, A., Kantola, I., Wilkins, M., Kobrin, I. A randomized, double-blind trial comparing mibefradil and amlodipine: Two long-acting calcium antagonists with similar efficacy but different tolerability profiles. J Hum Hypertension 1997, 11: 387-93.
41. Massie, B.M., Chrysant, S.G., Jain, A., Weir, M., Weiss, W., Kobrin, I. Antihypertensive effects of mibefradil: A double-blind comparison with diltiazem CD. Clin Cardiol 1997, 20: 562-8.
42. Reid, J.L., Petrie, J.R., Glen, S.K., Meredith, P.A., Elliott, H.L. Clinical pharmacology of the novel calcium antagonist mibefradil. J Cardiovasc Pharmacol 1996, 27(Suppl. A): S22-6.
43. Hoeglund, C., Watt, A., Wilkins, M., Tenszer, J., Cifkova, R., Mimram, A., Lindberg, E., Pordy, R. The effects of mibefradil on left ventricular hypertrophy in patients with essential hypertension. Amer J Hypertension 1997, 10(4, Part 2): 124A.
44. Chen, C., Peters, J., Welker, H., MacMahon, M. Pharmacodynamic and pharmacokinetic comparisons between mibefradil or enalapril monotherapy and the combined therapy in hypertensive patients. Pharmacol Res 1996, 13(9, Suppl.): Abst PPDM 8203.
45. Chen, C., Peters, J., Welker, H., Viskoper, I. Pharmacodynamic and pharmacokinetic interactions between mibefradil and atenolol in hypertensive patients. Pharmacol Res 1996, 13(9, Suppl.): Abst PPDM 8204.
46. Portegies, M.C.M., Schmitt, R., Kraaij, C.J. et al. Lack of negative inotropic effects of the new calcium antagonist Ro 40-5967 in patients with stable angina pectoris. J Cardiovasc Pharmacol 1991, 18: 746-51.
47. Bakx, A.L.M., van der Wall, E.E., Braun, S., Emanuelsson, H., Bruschke, A.V.G., Kobrin, I. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: A multicenter, placebo-controlled study. Amer Heart J 1995, 130: 748-57.
48. Tzivoni, D., Kadr, H., Braat, S., Rutsch, W., Ramires, J.A., Kobrin, I. Efficacy of mibefradil in comparison to amlodipine in suppressing exercise-induced and daily silent ischemia. Results of a multicenter, placebo-controlled trial. Circulation 1997, 96: 2557-64.
49. Schneeweiss, A., Caspi, A., Sclarovsky, S., Reisin, L., Marmor, A., Kobrin, I. Adding the new calcium antagonist mibefradil to patients on chronic β-adrenoceptor blocking treatment results in inprovement in antianginal and anti-ischemic efficacy. Cardiovasc Drugs Ther 1997, 11(Suppl. 2): 335.
50. Alpert, J.S., Kobrin, I., DeQuattro, V., Friedman, R., Shepherd, A., Fenster, P.E., Thadani, U. Additional antianginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta blocker for chronic stable angina pectoris. Amer J Cardiol 1997, 79: 1025-30.
51. Massie, B.M. Mibefradil a new calcium antagonist with novel pharmacological properties: Results in angina pectoris. Amer J Hypertension 1997, 10(4, Part 2): 239A.
52. Davies, G.J., Tzivoni, D., Kobrin, I. Mibefradil in the treatment of chronic stable angina pectoris: Comparative studies with other calcium antagonists. Amer J Cardiol 1997, 80: 34C-9C.
53. Caspi, A., Davies, G., Campos de Alburquerque, D., Kobrin, I. Long-term antianginal and anti-ischemic effects of mibefradil, the novel T-type calcium channel blocker: A multicenter, double-blind, placebo-controlled, randomized study versus diltiazem SR. Cardiovasc Drugs Ther 1997, 11(Suppl. 2): 335.
54. Rousseau, M.F., Hayashida, W., van Eyll, C., Hess, O.M., Benedict, C.R., Ahn, S., Chapelle, F., Kobrin, I., Pouleur, H. Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocking agent mibefradil in patients with varying degrees of left ventricular systolic dysfunction. J Amer Coll Cardiol 1996, 28: 972-9.
55. Van der Vring, J.A.F.M., Bernink, P.J.L.M., van der Wall, E.E., van Velhuisen, D.J., Braun, S., Kobrin, I. Evaluating the safety of mibefradil, a selective T-type calcium antagonist, in patients with congestive heart failure. Clin Ther 1996, 18: 1191-205.
56. Muntinga, H.J., van der Vring, J.A.F.M., Niemeyer, M.G., van der Berg, F., Knol, H.R., Benink, P.J.L.M., van der Wall, E.E., Blanksma, P.K., Lie, K.I. Effect of mibefradil on left ventricular diastolic function in patients with congestive heart failure. J Cardiovasc Pharmacol 1996, 27: 652-6.
57. Levine, T.B. The design of the mortality assessment in congestive heart failure trial (MACH-1, mibefradil). Clin Cardiol 1997, 20: 320-6.
58. First launch for Roche's Posicor. Prous Science Daily Essentials September 3, 1997.
59. German launch for Roche's mibefradil. Prous Science Daily Essentials October 22, 1997.
60. Bakx, A.L.M., van der Wall, E.E., Braun, S., Emanuelsson, H., Kobrin, I., Bruschke, A.V.G. Effects of a new calcium channel blocker Ro 40-5967 in patients with stable angina pectoris. Eur Heart J 1994, 15(Suppl.): Abst P1593.
61. Tzivoni, D., Braun, S., Caspi, A. et al. Mibefradil Ischaemia Suppression Trial (MIST): Results of a multicentre trial. Eur Heart J 1996, 17(Suppl.): Abst P3116.
62. van der Wall, E.E., Bakx, A.L.M., Braun, S., Emanuelsson, H., Bruschke, A.V.G., Kobrin, I. The effects of the new calcium antagonist mibefradil (Ro 40-5967), on exercise duration in patients with chronic stable angina pectoris: A multicenter, placebo-controlled study. 2nd Eur Meet Calcium Antagonists (Oct 25-27, Amsterdam) 1995, 29.
63. Chapelle, F., Stoleru, L., Hayashida, W., Etienne, J., Ahn, S., Pouleur, H., Hess, O., Benedict, C.R., Rousseau, M.F. Effects of a new calcium antagonist Ro40-5967 on left ventricular function in the presence or absence of congestive heart failure. Acta Cardiol 1994, 49(6): 515.
64. Chapelle, F., Stoleru, L., Hayashida, W., Pouleur, H., Hess, O., Benedict, C.R., Rousseau, M.F. Ro40-5967, a new calcium antagonist profile: Bradycardia without myocardial depression? Circulation 1994, 90(4, Part 2): Abst 0139.
65. van der Vring, J.A.F.M., Bernink, P.J.L.M., van der Wall, E.E., van Veldhuisen, D.J., Muntinga, H.J., Niemeyer, M.G., Lie, K.I. Double-blind, placebo-controlled study of increasing doses of mibefradil in patients with congestive heart failure: Effects on hemodynamic and neurohumoral parameters. 2nd Eur Meet Calcium Antagonists (Oct 25-27, Amsterdam) 1995, Abst 10.
66. van der Vring, J.A.F.M., Bernink, P.J.L.M., van der Wall, E.E., Braun, S., Lie, K.I. Safety and tolerability of ascending multiple doses of mibefradil in patients with congestive heart failure. J Heart Failure 1995, 2(1): Abst 144.
67. Muntinga, H.J., van der Vring, J., Niemeyer, M.G., van den Berg, F., Knol, H.R., Bernink, P.J.L.M., Kraay, C.J., Blanksma, P.K., Lie, K.I. Effect of mibefradil on left ventricular diastolic function in patients with congestive heart failure. 2nd Eur Meet Calcium Antagonists (Oct 25-27, Amsterdam) 1995, 27.
68. Chen, C., Welker, H., Peters, J., Eichler, H., Hultcrantz, R. Pharmacokinetics, pharmacodynamics and safety of Posicor in patients with liver cirrhosis or cholestasis. Pharm Res 1996, 13(9, Suppl.): Abst PPDM 8145.
69. Belz, G.G., Erb, K., Breithaupt, K., Butzer, R., Schmitt, R., Kleinbloesem, K. Pharmacodynamics of a calcium antagonist of a new chemical class. Clin Pharmacol Ther 1990, 47(2): Abst PIII-77.
70. Kirch, W., Kleinbloesem, C., Mescheder, A. Dose dependence of the calcium antagonist/digoxin interaction. Clin Pharmacol Ther 1993, 53(2): Abst PI-117.
71. Mescheder, A., Kleinbloesem, C. Dose dependence of the digoxin/ calcium antagonist interaction. Naunyn-Schmied Arch Pharmacol 1993, 347(Suppl.): Abst 144.
72. Siepmann, M., Kleinbloesem, C., Kirch, W. The interaction of the calcium antagonist Ro 40-5967 and digoxin. Brit J Clin Pharmacol 1995, 39: 491-6.
73. Kleinbloesem, C.H., Siepmann, M., Kirch, W. Hemolysis on intravenous administration of a new calcium antagonist. J Cardiovasc Pharmacol 1995, 25: 855-8.
74. Schmitt, R., Belz, G.G., Pozenel, H., Kirch, W., Woittiez, A.J.J., Kleinbloesem, C.H. Haemodynamic effects of the novel calcium agonist Ro 40-5967 in hypertensive patients. Brit J Clin Pharmacol 1991, 31: 578P.
75. Oparil, S., Abernethy, D.R., Levine, B.S., Reif, M.C., Shepherd, A.M., Kobrin, I. Dose-response characteristics of mibefradil, a selective T-type calcium channel blocker in the treatment of essential hypertension. Amer J Hypertension 1997, 10(4, Part 2): 23A.
76. Bursztyn, M., Oigman, W., Stephens, J.C., Tilvis, R., Kobrin, I. Mibefradil in elderly hypertensives: Favourable hemodynamics and pharmacokinetics. Amer J Hypertension 1997, 10(4, Part 2): 81A.
77. Carney, S., Wing, L., Kobrin, I. Adding mibefradil to hypertensive patients on chronic hydrochlorothiazide (HCTZ) treatment is associated with a significant antihypertensive effect. Amer J Hypertension 1997, 10(4, Part 2): 81A.
78. Lacourcière, Y., Poirier, L., Lefebvre, J., Archambault, F., Dalle Ave, S., Lindberg, E. Comparative effects of the novel calcium antagonist, mibefradil, and nifedipine GITS in patients with moderate to severe essential hypertension. Amer J Hypertension 1996, 9(4, Part 2): 156A.
79. Lacourcière, Y., Poirier, L., Lefebvre, J., Archambault, F., Lindberg, E. Efficacy of the novel calcium antagonist, mibefradil, in moderate-to-severe hypertensives with ambulatory hypertension. J Hypertension 1996, 14(Suppl. 1): Abst P967.
80. Viskoper, R.J., Bernink, P.J.L.M., Ziekenhuis, M., Schelling, A., Ribeiro, A.B., Kantola, I.M., Wilkins, M.R., Kobrin, I. A double-blind trial comparing mibefradil and amlodipine: Long acting calcium antagonists with similar efficacy but different tolerability profiles. Amer J Hypertension 1997, 10(4, Part 2): 81A.
81. Massie, B.M., Chrysant, S.G., Jain, A., Weir, M., Weiss, R., Kobrin, I. The antihypertensive effects of the selective T-type calcium channel blocker mibefradil: A double-blind comparison with diltiazem CD. Amer J Hypertension 1997, 10(4, Part 2): 82A.
82. 2+ channel in cardiac tissue. Eur J Pharmacol 1995, 280: 155-8.
83. Combs, K.A., Schwartz, A., Matlib, M.A. Ro40-5967, a structurally unique calcium antagonist, differentially affects dihydropyridine (DHP) and phenylalkylamine (PAA) binding sites of calcium channel. FASEB J 1994, 8(5, Part 2): Abst 5085.
84. Itagaki, K., Schwartz, A., Matlib, M.A. Binding of Ro40-5967, a structurally new calcium antagonist, to the calcium channel of skeletal muscle membranes. FASEB J 1994, 8(5, Part 2): Abst 5084.
85. 3H-mibefradil in vascular smooth muscle and heart membranes. Possible binding of mibefradil to a site distinct from the phenylalkylamine-binding site. Arzneim-Forsch-Drug Res 1996, 46: 953-5.
86. Lacinová, L., Welling, A., Hofmann, F. Ro 40-5967 and verapamil block calcium channel by different mechanisms. Naunyn-Schmied Arch Pharmacol 1994, 349(Suppl.): Abst 161.
87. Mehrke, G., Zong, X., Bosse, E., Hofmann, F. A T-type like Ca channel is inhibited by the non-dihydropyridine antagonist Ro 40-5967. Naunyn-Schmied Arch Pharmacol 1994, 349(Suppl.): Abst 160.
88. Lacinová, L., Welling, A., Bosse, E., Ruth, P., Flockerzi, V., Hofmann, F. Interaction of Ro 40-5967 and verapamil with the stably expressed alpha1-subunit of the cardiac L-type calcium channel. J Pharmacol Exp Ther 1995, 274: 54-63.
89. 2+ channels. J Pharmacol Exp Ther 1994, 271: 1483-8.
90. 2+ channel antagonist mibefradil (Ro 40-5967). Mol Pharmacol 1995, 48: 540-9.
91. 2+- and volume-activated Cl-channels in macrovascular endothelial cells. Brit J Pharmacol 1997, 121: 547-55.
92. + channels in the rat NG108-15 cell line. Brit J Pharmacol 1996, 117(Suppl.): Abst 116P.
93. Eberhard, M., Hermsmeyer, K., Erne, P. Effects of mibefradil on the calcium dynamics of rat cardiac fibroblasts and human platelets. Eur Heart J 1995, 16(Suppl.): Abst P399.
94. 2+ release in cultured rat cardiac fibroblasts and human platelets. Naunyn-Schmied Arch Pharmacol 1995, 353: 94-101.
95. Hahn, M., Tkachuk, V.A., Bochkov, V.N., Cheglakov, I.B., Clozel, J.-P. Blockade of receptor-operated calcium channels by mibefradil (Ro 40-5967): Effects on intracellular calcium and platelet aggregation. Cardiovasc Drugs Ther 1995, 9: 815-21.
96. Hensley, J., Altschuld, R.A., Billman, G.E. Effects of the calcium channel antagonists verapamil, nifedipine, and Ro 40-5967 on intracellular free calcium transients in isolated adult canine ventricular myocytes. FASEB J 1994, 8(5, Part 2): Abst 5086.
97. Simper, D., Zaugg, C.E., Zhu, P., Buser, P.T. Myocardial protection during ischemia and reperfusion of Ro 40-5967 and isradipine in comparison with diltiazem. Eur Heart J 1993, 14(Suppl.): Abst 1817.
98. Boulanger, C.M., Desta, B., Fisher, T., Vanhoutte, P.M. Ro 40-5967 causes endothelium-dependent relaxations of canine femoral arteries. Pharmacologist 1992, 34(3): Abst 72.
99. 2+ antagonistic vasodilator with functional endothelin antagonism. Jpn J Pharmacol 1994, 64(Suppl. 1): Abst P-223.
100. 2+ antagonist Ro 40-5967 on endothelium-dependent responses of isolated arteries. J Cardiovasc Pharmacol 1994, 23: 869-76.
101. Küng, C.F., Tschudi, M.R., Noll, G., Clozel, J.-P., Lüscher, T.F. Differential effects of the calcium antagonist mibefradil in epicardial and intramyocardial coronary arteries. J Cardiovasc Pharmacol 1995, 26: 312-8.
102. Sato, Y., Watanabe, H., Himori, N. Inhibition of induced contraction in the isolated rat mesenteric vascular bed by Ro 40-5967, a novel calcium antagonist. Folia Pharmacol Jpn 1995, 105: 171-6.
103. Karila-Cohen, D., Dubois-Randé, J.-L., Giudicelli, J.-F., Berdeaux, A. Effects of mibefradil on large and small coronary arteries in conscious dogs: Role of vascular endothelium. J Cardiovasc Pharmacol 1996, 28: 271-7.
104. Véniant, M., Clozel, J.-P., Hess, P., Wolfgang, R. Ro 40-5967, in contrast to diltiazem, does not reduce left ventricular contractility in rats with chronic myocardial infarction. J Cardiovasc Pharmacol 1991, 17: 277-84.
105. Billman, G.E. The effect of Ro 40-5967, a novel calcium channel antagonist on susceptibility to ventricular fibrillation. Circulation 1991, 84(4, Suppl. 2): Abst 2183.
106. Billman, G.E. Ro 40-5967, a novel calcium channel antagonist, protects against ventricular fibrillation. Eur J Pharmacol 1992, 229: 179-87.
107. Billman, G.E., Lappi, M.D., Hamlin, R.L. The effect of a novel calcium antagonist mibefradil on cardiac electrophysiological properties and susceptibility to ventricular fibrillation. FASEB J 1995, 9(3, Part 1): Abst 3495.
108. Billman, G.E., Hamlin, R.L. The effects of mibefradil, a novel calcium channel antagonist on ventricular arrhythmias induced by myocardial ischemia and programmed electrical stimulation. J Pharmacol Exp Ther 1996, 277: 1517-26.
109. Su, J., Renaud, N., Carayon, A., Crozatier, B., Hittinger, L., Laplace, M. Effects of the calcium channel blockers, diltiazem and Ro 40-5967, on systemic haemodynamics and plasma noradrenaline levels in conscious dogs with pacing-induced heart failure. Brit J Pharmacol 1994, 113: 395-402.
110. Richard, V., Tron, C., Blanc, T., Thuillez, C. Infarct size-limiting properties of Ro 40-5967, a novel nondihydropyridine calcium channel antagonist, in anesthetized rats: Comparison with verapamil. J Cardiovasc Pharmacol 1995, 25: 552-7.
111. Sabbah, H.N., Shimoyama, H., Tanimura, M., Shevlyagin, S., Levine, T.B., Goldstein, S. Intravenous mibefradil (Ro40-5967) improves haemodynamics in dogs with chronic heart failure: Comparison with diltiazem and placebo. Eur Heart J 1996, 17(Suppl.): Abst P457.
112. Roux, S., Bühler, M., Clozel, J.-P. Mechanism of the antiischemic effect of mibefradil, a selective T calcium channel blocker in dogs: Comparison with amlodipine. J Cardiovasc Pharmacol 1996, 27: 132-9.
113. Véniant, M., Clozel, J.-P., Heudes, D., Banken, L., Ménard, J. Effects of Ro-40-5967, a new calcium antagonist, and enalapril on cardiac remodeling in renal hypertensive rats. J Cardiovasc Pharmacol 1993, 21: 544-51.
114. Chida, M., Maeda, S., Song, C., Funada, J., Ono, S., Tanita, T., Voelkel, N.F., Fujimura, S. Antiinflammatory role of mibefradil on neutrophil-mediated lung eicosanoid production. FASEB J 1996, 10(3, Suppl.): Abst 3692.
115. i in human cerebral synaptosomes. Naunyn-Schmied Arch Pharmacol 1997, 356(4, Suppl. 1): Abst 23.
116. Billman, G.E. Mibefradil, a novel calcium channel antagonist, selectively protects against ventricular fibrillation induced by myocardial ischaemia. Eur Heart J 1997, 18(Suppl.): Abst P1039.
117. Cremers, B., Flesch, M., Südkamp, M., Horst, M., Böhm, M. Cardiodepressant potency of the new T-type calcium antagonist mibefradil in comparison with nifedipine and verapamil in failing human myocardium. Eur Heart J 1997, 18(Suppl.): Abst P3694.
118. Bernini, F., Canavesi, M., Bellosta, S., Ferri, N., Palmitano, A., Bernardini, E., Fumagalli, R., Corsini, A. Antiatherosclerotic activities of mibefradil in cell culture models. Atherosclerosis 1997, 134(1-2): Abst 1.P.172.